Evidence mapPaperPMID 39138689Full record

ReviewDiabetologia2024

Ageing well with diabetes: the role of technology.

Giuseppe Maltese, Sybil A McAuley, Steven Trawley, Alan J Sinclair

Abstract readReview
In one paragraph

Review in Diabetologia, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Review
  6. Observational
  7. Review
  8. Observational
  9. Review
  10. Life stage transitions for people with type 1 diabetes.The lancet. Diabetes & endocrinology · 2025
    Review
  11. Article
  12. Article
  13. Article
  14. Clin-STAR Corner: Practice Changing Advances in Diabetes Care.Journal of the American Geriatrics Society · 2025
    Review
  15. Review
  16. Article
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Giuseppe MalteseDepartment of Diabetes and Endocrinology, Epsom & St Helier University Hospitals NHS Trust, Surrey, UK. Giuseppe.maltese@kcl.ac.uk.
Sybil A McAuleySchool of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia.ORCID http://orcid.org/0000-0001-7035-489X
Steven TrawleyCairnmillar Institute, Melbourne, VIC, Australia.
Alan J SinclairFoundation for Diabetes Research in Older People (fDROP), Droitwich Spa, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Over the past two decades there has been a substantial rise in the adoption of diabetes therapeutic technology among children, adolescents and younger adults with type 1 diabetes, and its use is now also advocated for older individuals. Older people with diabetes are more prone to experience hypoglycaemia because of numerous predisposing factors and are at higher risk of hypoglycaemic events requiring third-party assistance as well as other adverse sequelae. Hypoglycaemia may also have long-term consequences, including cognitive impairment, frailty and disability. Diabetes in older people is often characterised by marked glucose variability related to age-associated changes such as variable appetite and levels of physical activity, comorbidities and polypharmacotherapy. Preventing hypoglycaemia and mitigating glucose excursions may have considerable positive impacts on physical and cognitive function and general well-being and may even prevent or improve frailty. Technology for older people includes continuous glucose monitoring systems, insulin pumps, automated insulin delivery systems and smart insulin pens. Clinical trials and real-world studies have shown that older people with diabetes benefit from technology in terms of glucose management, reductions in hypoglycaemic events, emergency department attendance and hospital admissions, and improvement in quality of life. However, ageing may bring physical impairments and other challenges that hinder the use of technology. Healthcare professionals should identify older adults with diabetes who may benefit from therapeutic technology and then adopt an individualised approach to education and follow-up for individuals and their caregivers. Future research should explore the impact of diabetes technology on outcomes relevant to older people with diabetes.

Indexed as

AgingDiabetes Mellitus, Type 1HypoglycemiaAgedBlood GlucoseBlood Glucose Self-MonitoringHumansHypoglycemic AgentsInsulinInsulin Infusion SystemsQuality of LifeBlood GlucoseHypoglycemic AgentsInsulinAgeingClosed loopContinuous glucose monitoringDiabetesDiabetes technologyFrailtyGlucose variabilityHypoglycaemiaOlder peopleReview

Identifiers

PMID39138689
PMCPMC11446974

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.